SHENZHEN, CHINA--(Marketwire - 11/26/10) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (www.htdsmedical.com) subsidiary Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) announces that, after four years of continuous effort, the registration of Cerebroprotein Hydrolysate for Injection (Cognistar) has been approved by India's drug regulator, Drugs Controller General of India (DCGI).
As soon as the approval is finalized, Mellow Hope (www.mellowhope.com/en/main.asp) will launch this product in the local market. Until this point there has been no local supplier in India for Cognistar, so the company anticipates healthy sales as it fills this market vacancy and claims a large market share. The company received permit to import this product to India, and copy of this certificate will be made available @ www.htdsmedical.com. The company will also post this certificate on OTCMarkets.Com as a filing shortly.
Cognistar is a unique nutriment for the brain. It regulates and improves nerve cell metabolism, promotes synapse generation, induces nerve cell differentiation, and protects nerve cells against damages by ischemia and neurotoxins.
The company is pleased at this approval after years of diligent research, and will keep the investor public updated as the first batches of Cognistar reach the Indian market.
In other company news and updates, regarding the news of November 22, 2010 and merger progress with a Canadian based Hb Products Inc. (Hb) the company is working diligently and vigorously to have the merger completed way ahead of the Christmas holidays. Currently a new updated web site is being developed to include Hb with a preview available at this link http://www.htdsmedical.com/new/.
The management will release further updates shortly as they become available.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment